Co-Morbidities of Psoriasis: Cardiovascular and Metabolic Syndrome, …

Alan Menter

PsO, PsA & Spondyloarthritis: Shared Cellular Immunopathology, the E…

Cleveland Clinic Department of Rheumatic and Immunologic Disease

D. Mcgonagle

The Clinical Heterogeneity of Psoriatic Arthritis in Adults

Dafna Gladman

Axial Disease in Psoriatic Arthritis: Clinical Presentation, Genetic…

Philip Helliwell

IL-23 Biologics: How Do These Inhibitors' Safety and Efficacy Compar…

Leon Kircik

Guselkumab and Reductions in Fatigue Severity in Patients With PsA: …

Laure Gossec

2021 Updates on PsA Management: Diagnosis, Assessment, and Current/ …

Cleveland Clinic Department of Rheumatic and Immunologic Disease

E. Husni

Psoriatic Arthritis Panel Discussion: ACR21

RheumNow

R. Tate, M. Ramahi, P. Castillo, A. Chan, O. Petryna, R. Chao, R. Conway

Instruments Measuring Physical Function for Active PsA: Overview of …

ACR Convergence 2021 Coverage

A. Ogdie

Psoriatic Disease: Risk Factors in People of Color

National Psoriasis Foundation

S. Desai

Efficacy and Safety of Phase III Trial of Guselkumab in PsA Patients…

RheumNow

Y. Yusof, L. Coates

Shared Management of Psoriatic Disease Roundtable, Part 2

National Psoriasis Foundation

E. Husni

A Year in Review: What Was New in Psoriasis Treatment in 2021 and Wh…

Joseph Merola

Treatment Responses in Patients With Psoriatic Arthritis Axial Disea…

Alexis Ogdie

Controversies in Psoriatic Arthritis: Methotrexate, Domain-Based App…

RheumNow

J. Cush, D. Gladman, J. Merola, P. Nash, C. Ritchlin, J. Scher

Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselk…

The Journal of Rheumatology

P. Rahman